TY - JOUR KW - Adolescent KW - Adult KW - Aged KW - Aged, 80 and over KW - Anti-Inflammatory Agents KW - Child KW - Fatty Acids, Unsaturated KW - Female KW - Host-Parasite Interactions KW - Humans KW - leprosy KW - Male KW - Metabolome KW - Middle Aged KW - Plasma KW - Skin KW - Young Adult AU - Amaral J AU - Antunes LCM AU - Macedo CS AU - Mattos KA AU - Han J AU - Pan J AU - Candéa A AU - Henriques MG AU - Ribeiro-Alves M AU - Borchers C AU - Sarno E AU - Bozza P AU - Finlay B AU - Pessolani MC AB -

Despite considerable efforts over the last decades, our understanding of leprosy pathogenesis remains limited. The complex interplay between pathogens and hosts has profound effects on host metabolism. To explore the metabolic perturbations associated with leprosy, we analyzed the serum metabolome of leprosy patients. Samples collected from lepromatous and tuberculoid patients before and immediately after the conclusion of multidrug therapy (MDT) were subjected to high-throughput metabolic profiling. Our results show marked metabolic alterations during leprosy that subside at the conclusion of MDT. Pathways showing the highest modulation were related to polyunsaturated fatty acid (PUFA) metabolism, with emphasis on anti-inflammatory, pro-resolving omega-3 fatty acids. These results were confirmed by eicosanoid measurements through enzyme-linked immunoassays. Corroborating the repertoire of metabolites altered in sera, metabonomic analysis of skin specimens revealed alterations in the levels of lipids derived from lipase activity, including PUFAs, suggesting a high lipid turnover in highly-infected lesions. Our data suggest that omega-6 and omega-3, PUFA-derived, pro-resolving lipid mediators contribute to reduced tissue damage irrespectively of pathogen burden during leprosy disease. Our results demonstrate the utility of a comprehensive metabonomic approach for identifying potential contributors to disease pathology that may facilitate the development of more targeted treatments for leprosy and other inflammatory diseases.

BT - PLoS neglected tropical diseases C1 - http://www.ncbi.nlm.nih.gov/pubmed/23967366?dopt=Abstract CN - AMARAL 2013 DA - 2013 DO - 10.1371/journal.pntd.0002381 IS - 8 J2 - PLoS Negl Trop Dis LA - eng N2 -

Despite considerable efforts over the last decades, our understanding of leprosy pathogenesis remains limited. The complex interplay between pathogens and hosts has profound effects on host metabolism. To explore the metabolic perturbations associated with leprosy, we analyzed the serum metabolome of leprosy patients. Samples collected from lepromatous and tuberculoid patients before and immediately after the conclusion of multidrug therapy (MDT) were subjected to high-throughput metabolic profiling. Our results show marked metabolic alterations during leprosy that subside at the conclusion of MDT. Pathways showing the highest modulation were related to polyunsaturated fatty acid (PUFA) metabolism, with emphasis on anti-inflammatory, pro-resolving omega-3 fatty acids. These results were confirmed by eicosanoid measurements through enzyme-linked immunoassays. Corroborating the repertoire of metabolites altered in sera, metabonomic analysis of skin specimens revealed alterations in the levels of lipids derived from lipase activity, including PUFAs, suggesting a high lipid turnover in highly-infected lesions. Our data suggest that omega-6 and omega-3, PUFA-derived, pro-resolving lipid mediators contribute to reduced tissue damage irrespectively of pathogen burden during leprosy disease. Our results demonstrate the utility of a comprehensive metabonomic approach for identifying potential contributors to disease pathology that may facilitate the development of more targeted treatments for leprosy and other inflammatory diseases.

PY - 2013 EP - e2381 T2 - PLoS neglected tropical diseases TI - Metabonomics reveals drastic changes in anti-inflammatory/pro-resolving polyunsaturated fatty acids-derived lipid mediators in leprosy disease. UR - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3744420/pdf/pntd.0002381.pdf VL - 7 SN - 1935-2735 ER -